Immuno Oncology Assays Market Analysis
The immuno Oncology assays market stands at USD 6.05 billion in 2025 and is forecast to reach USD 10.69 billion by 2030, reflecting a healthy 12.11% CAGR. Rising global cancer incidence, steady regulatory support for companion diagnostics, and accelerating adoption of spatial biology platforms combine to spur demand for sophisticated immune profiling tests. Growing pharma–diagnostic partnerships shorten validation timelines and expand test menus, while artificial intelligence (AI) integration strengthens assay accuracy and throughput. North America maintains leadership through favorable reimbursement, but Asia-Pacific records the fastest uptake as healthcare infrastructure matures and clinical trial activity rises. Competitive strategies increasingly hinge on multi-omics integration and real-world evidence generation, positioning agile technology providers to capture sizeable share in community oncology settings.
Key Report Takeaways
- By product, Reagents & Antibodies led with 40.12% of immuno-oncology assays market share in 2024; Software & Analytics is projected to grow at a 12.67% CAGR through 2030.
- By technology, Next-Generation Sequencing held 37.67% revenue share of the immuno-oncology assays market in 2024, while Multiplex Spatial Profiling is set to expand at a 12.71% CAGR to 2030.
- By assay type, Laboratory-Developed Tests accounted for 51.23% share of the immuno-oncology assays market size in 2024; Companion Diagnostics show the highest forecast CAGR at 12.69% through 2030.
- By indication, Lung Cancer commanded 32.12% of immuno-oncology assays market size in 2024, whereas Breast Cancer is anticipated to grow at a 12.91% CAGR between 2025 and 2030.
- By sample type, Tissue Biopsy retained 53.12% share of the global immuno-oncology assays market in 2024; Liquid Biopsy is expected to post a 12.74% CAGR to 2030.
- By geography, North America captured 42.34% of the immuno-oncology assays market in 2024; Asia-Pacific represents the fastest-growing region with a 12.86% CAGR to 2030.
Global Immuno Oncology Assays Market Trends and Insights
Drivers Impact Analysis
| Driver | % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Sustained rise in global cancer incidence | 2.8% | Global, with highest impact in aging populations of North America, Europe, and Asia-Pacific | Long term (≥ 4 years) |
| Expanding adoption of immune-checkpoint inhibitors | 2.4% | Global, led by North America and Europe, expanding to Asia-Pacific | Medium term (2-4 years) |
| Regulatory approvals of companion Dx assays (PD-1/PD-L1, TMB) | 2.1% | North America and Europe primarily, with spillover to Asia-Pacific | Short term (≤ 2 years) |
| Pharma-Dx co-development partnerships accelerating test menus | 1.9% | Global, concentrated in major pharmaceutical hubs | Medium term (2-4 years) |
| AI-driven multiplex spatial profiling boosting biomarker discovery | 1.7% | North America and Europe core, expanding to Asia-Pacific | Long term (≥ 4 years) |
| Decentralised liquid-biopsy testing in community oncology | 1.2% | North America primarily, with gradual expansion to other regions | Medium term (2-4 years) |
| Source: | |||
Expanding Adoption of Immune-Checkpoint Inhibitors
Immune-checkpoint inhibitors reshape the therapeutic landscape, prompting wider deployment of companion tests that gauge PD-L1 status, tumor mutational burden, and microsatellite stability. Multiple FDA approvals in 2025, such as tislelizumab plus chemotherapy for esophageal squamous cell carcinoma and pembrolizumab-trastuzumab for HER2-positive gastric cancer, emphasise the need for robust predictive assays. The Society for Immunotherapy of Cancer lists biomarker panels that now guide routine clinical decision-making. Spatial omics platforms further refine response prediction, enabling multidimensional tumour micro-environment analysis that elevates assay specificity.
AI-Driven Multiplex Spatial Profiling Boosting Biomarker Discovery
Coupling AI with spatial biology technology uncovers cellular interactions previously hidden by conventional approaches. The Garvan Institute’s AAnet tool exemplifies this progress by differentiating five tumour-resident cell types to inform therapeutic strategies. Commercial systems such as the Hyperion XTi Imaging Mass Cytometer visualise 40+ markers simultaneously without autofluorescence noise, fostering deeper biomarker pipelines. Research in Molecular Cancer confirms that high-resolution 3D histology enhances understanding of tumour heterogeneity, accelerating assay innovation.
Regulatory Approvals of Companion Dx Assays (PD-1/PD-L1, TMB)
Recent FDA clearances, including the therascreen KRAS RGQ PCR kit for KRAS G12C mutations and the VENTANA MET (SP44) assay for c-Met expression, underscore a regulatory shift toward multi-parameter diagnostics. Breakthrough device designation for the Ventana TROP2 assay demonstrates how AI-enabled pathology speeds approval cycles. Expanded menus strengthen the immuno-oncology assays market by offering clinicians validated tools that match evolving therapy algorithms.
Pharma-Dx Co-Development Partnerships Accelerating Test Menus
Collaboration between drug developers and assay companies compresses R&D timelines. GeneCentric and Labcorp co-develop RNA gene signatures, marrying large clinical datasets with molecular analytics. Guardant Health and ConcertAI integrate 5.5 million real-world records with epigenomic profiles to refine evidence generation. These alliances reduce the cost and complexity of bringing novel biomarkers to market, expanding the immuno-oncology assays market footprint.
Restraints Impact Analysis
| Restraint | % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| High assay costs & complex reimbursement pathways | -1.8% | Global, most pronounced in cost-sensitive markets and emerging economies | Medium term (2-4 years) |
| Stringent multi-jurisdiction regulatory validation demands | -1.4% | Global, with highest impact in markets requiring multiple regulatory approvals | Long term (≥ 4 years) |
| Scarcity of well-annotated matched tumour/normal biobanks | -1.1% | Global, particularly affecting research-intensive regions | Long term (≥ 4 years) |
| Lack of global standardisation in multiplex assay protocols | -0.9% | Global, with fragmentation most evident in emerging markets | Medium term (2-4 years) |
| Source: | |||
High Assay Costs & Complex Reimbursement Pathways
Sharp increases in Medicare claim denial rates for NGS—from 16.8% to 27.4% in 2025—illustrate tightening US payer scrutiny. Capital investment exceeding USD 500,000 for full spatial-profiling setups further limits diffusion in community settings. Health technology assessments in Europe add 12-18 months to launch timelines, increasing financial risk for smaller developers. Consequently, price-tiering strategies become essential to sustain uptake in cost-sensitive regions.
Stringent Multi-Jurisdiction Regulatory Validation Demands
Divergent criteria among the FDA, EMA, and other regulators elongate validation cycles. Inter-lab coefficient-of-variation above 20% for PD-L1 testing highlights reproducibility hurdles. Organisations such as CIMAC-CIDC continue to explore harmonisation, yet localisation requirements inflate operational overheads. These obstacles temper the otherwise strong growth trajectory of the immuno-oncology assays market.
Segment Analysis
By Product: Reagents Dominate, Software Accelerates
Reagents & Antibodies captured 40.12% of the immuno-oncology assays market in 2024, evidencing the consumable-heavy nature of immune testing workflows. Hospital and reference laboratories turn to validated antibody panels to meet SITC-endorsed biomarker requirements. Instruments enjoy steady demand as labs upgrade to imaging-mass-cytometry platforms capable of 40-plus marker detection.
Software & Analytics, projected to post a 12.67% CAGR through 2030, benefits from AI modules that automate cell-phenotype mapping and cloud-based data sharing. The Garvan Institute’s AAnet and similar solutions lower analysis times, creating new revenue streams for digital pathology vendors. This software upsurge diversifies revenue composition within the immuno-oncology assays market.
By Technology: NGS Leads, Spatial Profiling Transforms
Next-Generation Sequencing retained 37.67% share of the immuno-oncology assays market in 2024, remaining indispensable for broad mutational scans. High-depth panel sequencing supports tumour mutational burden calculation, directly guiding checkpoint inhibitor use.
Multiplex Spatial Profiling, forecast to grow at 12.71% CAGR, permits single-cell resolution mapping of protein and RNA markers within intact tissues. Illumina’s whole-transcriptome spatial platform highlights this shift toward context-rich analytics. Immunoassay, PCR, and flow cytometry modalities maintain complementary roles for targeted or high-throughput applications, collectively sustaining technology diversity inside the immuno-oncology assays market.
By Assay Type: LDTs Dominate, CDx Gains Momentum
Laboratory-Developed Tests held 51.23% of immuno-oncology assays market share in 2024, reflecting academic centers’ need for flexible assay design. Custom panels support exploratory research on neo-antigens and immune evasion pathways.
Regulatory acceleration in companion diagnostics fuels a 12.69% CAGR for CDx through 2030. FDA clearance of the VENTANA MET (SP44) assay and similar tests formalises biomarker criteria for therapy eligibility, driving clinical demand. Research-Use-Only panels continue to seed discovery pipelines, indirectly bolstering long-term market vitality.
By Indication: Lung Cancer Leads, Breast Cancer Accelerates
Lung Cancer generated 32.12% of immuno-oncology assays market size in 2024 thanks to established guidelines mandating PD-L1, KRAS, and EGFR profiling. High global incidence rates sustain testing volumes.
Breast Cancer is poised for a 12.91% CAGR as HER2-low, HER2-ultra-low, and immune biomarkers expand clinical decision trees. FDA approval of fam-trastuzumab deruxtecan-nxki, paired with the Ventana PATHWAY anti-HER-2 assay, underscores broader biomarker adoption. Growth across colorectal, melanoma, and other tumour types rounds out indication-level opportunity in the immuno-oncology assays market.
By Sample Type: Tissue Rules, Liquid Biopsy Transforms
Tissue Biopsy accounted for 53.12% share of the immuno-oncology assays market in 2024, supported by well-established protocols and rich histopathology context. Comprehensive tissue profiling remains the clinical gold standard for staging and therapeutic planning.
Liquid Biopsy’s forecast 12.74% CAGR reflects advances in circulating tumour DNA, exosome, and methylation assays. Guardant360 Tissue’s launch, analysing 1,100-plus DNA and RNA genes with 40% less material, exemplifies efficiency gains. Non-invasive monitoring augments, rather than replaces, tissue testing, reinforcing multimodal sampling across the immuno-oncology assays market.
Geography Analysis
North America generated 42.34% of 2024 global revenue through favourable reimbursement, early AI adoption, and dense networks of comprehensive cancer centres. Medicare’s evolving coverage for NGS diagnostics still poses short-term reimbursement uncertainty, but strong private-payer frameworks keep overall growth intact.
Europe maintains balanced progress as health technology assessments verify clinical benefit before wide rollout. EMA’s approval of agents such as tislelizumab shows regional commitment to immunotherapeutic expansion[1]European Medicines Agency, “Tevimbra (tislelizumab) Authorization,” ema.europa.eu. Although multiple national approval layers can delay diagnostics launches, streamlined EU IVDR-compliant pathways promise to shorten time-to-market after 2026.
Asia-Pacific leads growth at a 12.86% CAGR as China deploys national cancer screening programs and Japan subsidises genomic testing. Emerging precision-medicine hubs in India and South Korea further stimulate demand. Simplified regulatory fast-tracks for innovative devices improve access, giving international suppliers a sizeable addressable base in the immuno-oncology assays market.
Middle East & Africa witnesses incremental uptake as Gulf states invest in oncology centres of excellence and procure multiplex platforms. South America records steady progress, led by Brazil’s public-private oncology partnerships and Argentina’s inclusion of genomic testing in national guidelines. Varying reimbursement coverage still restricts volume but long-term incidence trends underpin latent demand.
Competitive Landscape
The immuno-oncology assays market is moderately consolidated. Thermo Fisher Scientific’s USD 3.1 billion acquisition of Olink integrates high-throughput proteomics with existing NGS kits, reinforcing end-to-end service capability[2]Financial Times, “Thermo Fisher Moves into Proteomics with Olink Deal,” ft.com. Veracyte’s USD 95 million purchase of C2i Genomics extends into minimal residual disease monitoring.
Technology differentiation centres on AI-enabled multiplex imaging and data integration. Owkin’s TLS Detect achieves 97% sensitivity in detecting tertiary lymphoid structures, positioning the firm as a reference for spatial AI analytics[3]Owkin, “TLS Detect: AI Biomarker for Immunotherapy,” owkin.com. Guardant Health’s partnership with ConcertAI merges expansive electronic medical records with molecular data, advancing real-world evidence and payer acceptance.
White-space innovation targets decentralised workflows. Companies such as Mursla Bio focus on extracellular vesicle-based assays tailored for organ-specific signatures, complementing central lab services. Mid-size players leverage ISO-accredited manufacturing and regional distribution to serve hospitals adopting comprehensive immune panels. As clinical utility broadens, market success will favour firms that deliver integrated, regulator-ready, and clinician-friendly solutions.
Recent Industry Developments
- July 2025: FDA granted accelerated approval to sunvozertinib (Zegfrovy) for metastatic NSCLC with EGFR exon 20 insertions; Oncomine Dx Express Test approved as companion diagnostic.
- May 2025: Roche obtained FDA approval for VENTANA MET (SP44) RxDx assay as first companion diagnostic for MET protein in non-squamous NSCLC.
- April 2025: Ventana TROP2 (EPR20043) RxDx assay received breakthrough device designation for datopotamab deruxtecan selection in NSCLC.
- April 2025: Guardant Health launched Guardant360 Tissue multiomic profiling test analysing 742 DNA and 367 RNA genes while using fewer slides.